• Title, Summary, Keyword: Targeted Drug Delivery System

Search Result 24, Processing Time 0.041 seconds

Position Control of Capsule Filled with Magnetic Fluid for Targeted Drug Delivery System (지적투약시스템을 위한 자성유체 캡슐의 위치 제어)

  • Ahn Chang-ho;Nam Yun-Joo;Park Myeong-Kwan
    • Transactions of the Korean Society of Mechanical Engineers A
    • /
    • v.28 no.8
    • /
    • pp.1166-1173
    • /
    • 2004
  • In this paper, in order to apply magnetic fluid with superparamagnetic property as the substitute of ferromagnetic materials, physical properties of magnetic fluid are investigated. A targeted drug delivery system using a capsule filled magnetic fluid is proposed where a magnetic fluid capsule and cylinders are considered as a drug and vital organs, respectively. The dynamic governing equation of this system first is derived. Fluid viscosity, clearance between a cylinder and a magnetic fluid capsule, and levitation height with respect to different cylinder height are considered as major parameters to evaluate dynamic characteristics of the system. The experiments and simulations for the position control of the magnetic fluid capsule in various cylinders are conducted using PID controller. The results show that magnetic fluid with the superparamagnetic property can be applied to a targeted drug delivery system.

Recent Progress in Drug Delivery Systems for Anticancer Agents

  • Kim, Chong-Kook;Lim, Soo-Jeong
    • Archives of Pharmacal Research
    • /
    • v.25 no.3
    • /
    • pp.229-239
    • /
    • 2002
  • Recent progress in understanding the molecular basis of cancer brought out new materials such as oligonucleotides, genes, peptides and proteins as a source of new anticancer agents. Due to their macromolecular properties, however, new strategies of delivery for them are required to achieve their full therapeutic efficacy in clinical setting. Development of improved dosage forms of currently marketed anticancer drugs can also enhance their therapeutic values. Currently developed delivery systems for anticancer agents include colloidal systems (liposomes, emulsions, nanoparticles and micelles), polymer implants and polymer conjugates. These delivery systems have been able to provide enhanced therapeutic activity and reduced toxicity of anticancer agents mainly by altering their pharmacokinetics and biodistribution. Furthermore, the identification of cell-specific receptor/antigens on cancer cells have brought the development of ligand- or antibody-bearing delivery systems which can be targeted to cancer cells by specific binding to receptors or antigens. They have exhibited specific and selective delivery of anticancer agents to cancer. As a consequence of extensive research, clinical development of anticancer agents utilizing various delivery systems is undergoing worldwide. New technologies and multidisciplinary expertise to develop advanced drug delivery systems, applicable to a wide range of anticancer agents, may eventually lead to an effective cancer therapy in the future.

Gene Medicine : A New Field of Molecular Medicine

  • Kim, Chong-Kook;Haider, Kh-H;Lim, Soo-Jeong
    • Archives of Pharmacal Research
    • /
    • v.24 no.1
    • /
    • pp.1-15
    • /
    • 2001
  • Gene therapy has emerged as a new concept of therapeutic strategies to treat diseases which do not respond to the conventional therapies. The principle of gene therapy is to Introduce genetic materials into patient cells to produce therapeutic proteins in these cells. Gene therapy is now at the stage where a number of clinical trials have been carried out to patients with gene-deficiency disease or cancer. Genetic materials for gene therapy are generally composed of gene expression system and gene delivery system. For the clinical application of gene therapy in a way which conventional drugs are used, researches have been focused on the design of gene delivery system which can offer high transfection efficiency with minimal toxicity. Currently, viral delivery systems generally provide higher transfection efficiency compared with non-viral delivery systems while non-viral delivery systems are less toxic, less immunogenic and manufacturable in large scale compared with viral systems. Recently, novel strategies towards the design of new non-viral delivery system, combination of viral and non-viral delivery systems and targeted delivery system have been extensively studied. The continued effort in this area will lead us to develop gene medicine as "gene as a drug" in the near future.

  • PDF

Folate-Targeted Nanostructured Lipid Carriers (NLCs) Enhance (Letrozol) Efficacy in MCF-7 Breast Cancer Cells

  • Sabzichi, Mehdi;Mohammadian, Jamal;Khosroushahi, Ahmad Yari;Bazzaz, Roya;Hamishehkar, Hamed
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.12
    • /
    • pp.5185-5188
    • /
    • 2016
  • Objective: Targeted-drug-delivery based lipid nanoparticles has emerged as a new and effective approach in cancer chemotherapy. Here, we investigated the ability of folate-modified nanostructured lipid carriers (NLCs) to enhance letrozol (LTZ) efficacy in MCF-7 breast cancer cells. Methods: New formulations were evaluated regarding to particle size and scanning electron microscope (SEM) features. Anti-proliferative effects of LTZ loaded nanoparticles were examined by MTT assay. To understand molecular mechanisms of apoptosis and cell cycle progression, flow cytometric assays were applied. Results: Optimum size of nanoparticles was obtained in mean average of $98{\pm}7nm$ with a poly dispersity index (PDI) of 0.165. The IC50 value was achieved for LTZ was $2.2{\pm}0.2{\mu}M$. Folate-NLC-LTZ increased the percentage of apoptotic cells from 24.6% to 42.2% compared LTZ alone (p<0.05). Furthermore, LTZ loaded folate targeted NLCs caused marked accumulation of cells in the subG1 phase. Conclusion: Taken together, our results concluded that folate targeted LTZ can be considered as potential delivery system which may overcome limitations of clinical application of LTZ and improve drug efficacy in tumor tissue.

Nano-sized Drug Carriers and Key Factors for Lymphatic Delivery

  • Choi, Ji-Hoon;Lee, Yong-Bok
    • Journal of Pharmaceutical Investigation
    • /
    • v.40 no.spc
    • /
    • pp.75-82
    • /
    • 2010
  • Specific diseases like cancer and acquired immune deficiency syndrome (AIDS) occur at various organs including lymphatics and spread through lymphatic system. Thus, if therapeutic agents for such diseases are more distributed or targeted to lymphatic system, we can obtain several advantages like reduction of systemic side effect and increase of efficacy. For these reasons, much interest has been focused on the nature of lymphatics and a lot of studies for lymphatic delivery of drugs have been carried out. Because lymphatics consist of single layer endothelium and have high permeability compared with blood capillaries, especially, the studies using nano-sized carriers have been performed. Polymeric nano-particle, liposome, and lipid-based vehicle have been adopted for lymphatic delivery as carriers. According to the administration route and the kind of carrier, the extent of lymphatic delivery efficiency of nano-sized carriers has been changed and influenced by several factors such as size, charge, hydrophobicity and surface feature of carrier. In this review, we summarized the key factors which affect lymphatic uptake and the major features of carriers for achieving the lymphatic delivery. Lymphatic delivery of drug using nano-sized carriers has many fold improved ability of lymphatic delivery compared with that of conventional dosage forms, but it has not shown whole lymph selectivity yet. Even though nano-sized carriers still have the potential and worth to study as lymphatic drug delivery technology as before, full understanding of delivery mechanism and influencing factors, and setting of pharmacokinetic model are required for more ideal lymphatic delivery of drug.

Evaluation of the cytotoxicity of gold nanoparticle-quercetin complex and its potential as a drug delivery vesicle

  • Pak, Pyo June;Go, Eun Byeol;Hwang, Min Hee;Lee, Dong Gun;Cho, Mi Ju;Joo, Yong Hoon;Chung, Namhyun
    • Journal of Applied Biological Chemistry
    • /
    • v.59 no.2
    • /
    • pp.145-147
    • /
    • 2016
  • Recently, conjugates of medicinal herb-derived bioflavonoids, such as quercetin, and gold nanoparticles (GNPs) have gained attention as targeted drug delivery systems. In the present study, because quercetin is an important flavonoid with anti-cancer, anti-inflammatory, and anti-oxidant properties, GNP-quercetin complexes (GNPQs) were synthesized to investigate possible adverse effects such as cytotoxicity. We found that while quercetin was cytotoxic, GNPQs were not cytotoxic towards the RAW 264.7 and THP-1 cell lines. Therefore, GNPQs may serve as a potential drug delivery system for cancer treatment.

Hyaluronic Acid in Drug Delivery Systems

  • Jin, Yu-Jin;Ubonvan, Termsarasab;Kim, Dae-Duk
    • Journal of Pharmaceutical Investigation
    • /
    • v.40 no.spc
    • /
    • pp.33-43
    • /
    • 2010
  • Hyaluronic acid (HA) is a biodegradable, biocompatible, non-toxic, non-immunogenic and non-inflammatory linear polysaccharide, which has been used for various medical applications including arthritis treatment, wound healing, ocular surgery, and tissue augmentation. Because of its mucoadhesive property and safety, HA has received much attention as a tool for drug delivery system development. It has been used as a drug delivery carrier in both nonparenteral and parenteral routes. The nonparenteral application includes the ocular and nasal delivery systems. On the other hand, its use in parenteral systems has been considered important as in the case of sustained release formulation of protein drugs through subcutaneous injection. Particles and hydrogels by various methods using HA and HA derivatives as well as by conjugation with other polymer have been the focus of many studies. Furthermore, the affinity of HA to the CD44 receptor which is overexpressed in various tumor cells makes HA an important means of cancer targeted drug delivery. Current trends and development of HA as a tool for drug delivery will be outlined in this review.

Synthesis, Characterization and In Vitro Evaluation of Triptolide-lysozyme Conjugate for Renal Targeting Delivery of Triptolide

  • Zheng, Qiang;Gong, Tao;Sun, Xun;Zhang, Zhi-Rong
    • Archives of Pharmacal Research
    • /
    • v.29 no.12
    • /
    • pp.1164-1170
    • /
    • 2006
  • A triptolide-lysozyme (TP-LZM) conjugate was synthesized to achieve renal specific delivery and to reduce the side effects of triptolide. Triptolide was coupled to lysozyme through succinic via an ester bond with an average coupling degree of 1 mol triptolide per 1 mol lysozyme. The lysozyme can specifically accumulate in the proximal tubular cells of the kidney, making it a potential carrier for targeting drugs to the kidney. The structure of triptolide succinate (TPS) was confirmed by IR, $^{1}H-NMR$, MS and UV. The concentrations of triptolide in various samples were determined by reversed-phase high-performance liquid chromatography (HPLC). In this study, the physicochemical and stability profiles of TP-LZM under various conditions were investgated the stability and releasing profiles of triptolide-lysozyme (TP-LZM) under various conditions. In vitro release trails showed triptolide-lysozyme was relatively stable in plasma (less than 30% of free triptolide released) and could release triptolide quickly in lysosome (more than 80% of free triptolide released) at $37^{\circ}C$ for 24 h. In addition, the biological activities of the conjugate on normal rat kidney proximal tubular cells (NRK52E) were also tested. The conjugate can effectively reduce NO production in the medium of NRK52E induced by lipopolysaccharide (LPS) but with much lower toxicity. These studies suggest the possibility to promote curative effect and reduce its extra-renal toxicity of triptolide by TP-LZM conjugate.

Preparation and anticancer effect of transferrin-modified pH-sensitive polymeric drug nanoparticle for targeted cancer therapy

  • Kim, Tae-Hun;Jeong, Gyeong-Won;Nah, Jae-Woon
    • Journal of Industrial and Engineering Chemistry
    • /
    • v.54
    • /
    • pp.298-303
    • /
    • 2017
  • The doxorubicin-conjugated O-carboxymethyl chitosan (OCAD) was synthesized by hydrazone bond and transferrin was introduced to OCAD for targeted cancer therapy. The OCAD was analyzed by $^1H$ NMR and, diameter of OCAD and TPOCAD were confirmed 230 nm and 250 nm by DLS, respectively. The release profile of OCAD showed that acidic pH was rapidly released than neutral pH. To compare cellular uptake of OCAD and TPOCAD, its internalization was analyzed by CLSM. In addition, cytotoxicity of TPOCAD was accomplished by MTT assay. Therefore, TPOCAD-polymeric drug has a potential ability as drug delivery system for effective chemotherapy against cancer cells.